Bioporto A/s · OMXCOP:BIOPOR
Bioporto A/s — Q1 2025 Earnings Presentation
17 slides from Bioporto A/s's earnings presentation, May 8, 2025
Slide 1: Interim report Q1 2025 Investor Presentation
Interim report Q1 2025 Investor Presentation BioPorto A/S Hellerup, May 8, 2025 1
Slide 2: Forward-looking statements
Forward-looking statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matte
Slide 3: Highlights for Q1 2025
Highlights for Q1 2025 TOTAL REVENUE (Q1 2025) ✓ Revenue in line with expectations following a shift in bulk order timing from Q1 DKK 7.7 million 2025 to later in 2025 A decrease of 19% compared to ✓ US NGAL sales continued to increase in the first quarter and were up 20% Q1 2024 compared to the sam
Slide 4: Status on commercial launch and adult study
Status on commercial launch and adult study
Slide 5: Strengthening of commercial platform
Strengthening of commercial platform • Optimized the leadership team to further strengthening our commercial platform and effectiveness • Converting NGAL awareness to actual demand is expanding the pipeline both in the US and Europe • Conference attendance and a high level of sales activities are ge
Slide 6: Enrollment of patients for adult ProNephro AKI (NGAL) progressing ahead of expectations
Enrollment of patients for adult ProNephro AKI (NGAL) are progressing ahead of expectations • First patient for adult usage of ProNephro AKI (NGAL) enrolled in late 2024 at Massachusetts General Hospital – well ahead of original schedule • Patient enrollment at the 12 hospital sites are progressing
Slide 7: Financial results Q1 2025
Financial results Q1 2025
Slide 8: Solid US revenue growth in Q1 2025 vs Q1 2024
Solid US revenue growth in Q1 2025 vs Q1 2024 Revenue Q1 2025 vs Q1 2024, DKKm Revenue per quarter, DKKm -19% -1.8m 9.7 +20% 9.5 9.2 9.5 US NGAL 8.6 8.0 7.8 7.7 7.7 7.7 -25% -1.5m 6.6 6.1 -6% 4.6 -0.2m 2.7 2.5 -18% -0.1m 0.7 0.6 Total NGAL Test Antibodies Others Q1 Q2 Q3 Q4 Q1 2024 Q1 2025 2023 2024
Slide 9: The fast-progressing clinical study impacts adjusted EBITDA loss
The fast-progressing clinical study impacts adjusted EBITDA loss Adjusted EBITDA loss, DKKm • Adjusted EBITDA loss of 28.1 DKK 28.1m in Q1 2025 19.6 19.5 vs. DKK 15.3m in Q1 15.3 16.2 2024 • EBITDA loss increased in Q1 2025 due to costs Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 for the adult clinical
Slide 10: Closing of second funding round in April 2025
Closing of second funding round in April 2025 • On April 15, BioPorto successfully completed a direct issuance of 25,000,000 new shares at market price, providing net proceeds of 33,505,000, despite challenging financial market conditions • This marked the second funding round in the effort to raise
Slide 11: Strategic roadmap and milestones towards 2029
Strategic roadmap and milestones towards 2029
Slide 12: Strategic milestones towards 2029
Strategic milestones towards 2029 Strategic initiatives Targets for 2025-2026 Targets for 2027-2029 • Commercial launch of NGAL test in the US and drive usage • Commercialization of ProNephro AKI (NGAL) for Building pediatrics/young adults (US) Adult use in US Commercial • Consolidate Adult usage in
Slide 13: Important future milestones
Important future milestones Fundraising to fund First patient US First patient US Last patient US FDA submission Expected US FDA clearance process enrollment for enrollment for enrollment for of ProNephro clearance for for ProNephro AKI adult study adult study adult study AKI (NGAL) for ProNephro AK
Slide 14: Financial outlook
Financial outlook
Slide 15: 2025 Financial outlook
2025 Financial outlook • Expected revenue growth of 24-66% in 2025 driven by Target total revenue in 2025 Adjusted EBITDA loss in 2025 • Increased sales of NGAL products – primarily in the US • Revenue in 2025 will be back-end loaded • Higher expected adjusted DKK 45-60 DKK 75-85 EBITDA loss in 2025
Slide 16: Aspirations of targeting USD +100 million revenue in 2029
Aspirations of targeting USD +100 Until 2026 million revenue in 2029 • Total revenue of DKK 80-125m by expanding ProNephro AKI (NGAL) sales • Cash flow positive & EBITDA neutral by • Revenue: DKK +700m (USD +100m) end 2026 at the earliest • Increasing profitability • Cash flow positive Towards 2029
Slide 17: Q&A Contact
Q&A Contact Niels H. Nielsen, CFO – nhn@bioporto.com Hanne S. Foss, Head of Investor Relations – hsf@bioporto.com +45 4529 0000 | bioporto.com